Eric Jing: Ant Group to Strengthen Support for Hong Kong's Global Finance and Tech Leadership with AI, GoGlobal Services
3.11.2025 09:19:00 CET | Business Wire | Press Release
Eric Jing, Chairman of Ant Group, reaffirmed Ant’s commitment to deepening cross-sector collaboration on regulated AI and tokenization innovation in the territory, and to expanding its cross-border payment and trade financing services to support Hong Kong’s initiative to help Chinese businesses go global.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102787084/en/
John Lee, Chief Executive of Hong Kong SAR visited the booths of Ant International and Ant Digital Technologies during the 10th annual Hong Kong Fintech Week on November 3, 2025.
Speaking on a panel with Christopher Hui, Hong Kong’s Secretary for Financial Services and the Treasury, and Fred Hu, Founder, Chairman and CEO of Primavera Capital Group at the 10th annual Hong Kong Fintech Week on November 3, 2025, Jing said the City’s visionary and prudent approach to policy innovation, rich commercial and financial use cases and a robust ecosystem of cross-sector collaboration constitute a strong foundation for the City’s continued global leadership.
Ant Group took its first steps in Hong Kong when Chinese consumers and travellers began to make cross-border payments online and offline in Hong Kong with Alipay. Today, Hong Kong is a critical globalization anchor for Ant Group and its main affiliates, including Ant Digital Technologies, Ant International, and OceanBase, a distributed database technology provider.
AI and Tokenization Driving Evolution of Finance
“AI and tokenization are the two of the most critical forces driving the evolution of financial services,” said Jing. “Hong Kong regulators are leading the global experiment in both areas through visionary and prudent policy mechanisms.”
“Financial services are data-rich and language-heavy, relying on precise communication of abstract and complex products. Nevertheless, the pace of change is faster and faster. In the mid-term, we will be able to see the rise of full AI account managers supported by agentic systems,” Jing said.
While AI will help build accessible and quality professional financial services for billions, blockchain-based tokenization technology also demonstrates proven potential to realize secure and reliable global real-time settlement to improve trade efficiency for economies large and small.
“The trend for tokenization in fintech is not for speculation, but for regulated institutions to work within the policy framework to improve real efficiency and transparency in value exchange,” Jing said.
Ant Expanding Collaboration in Hong Kong on AI & Blockchain Innovation
Ant Group’s digital technology subsidiary, Ant Digital Technologies (AntDT), is a key participant of HKMA's GenAI Sandbox to support banks' adoption of AI agents, and apply AI to unstructured data to develop enhanced risk management and anti-fraud solutions.
Early in 2025, AntDT announced a series of new initiatives from its international headquarters in Hong Kong. AntDT established a joint AI and Web3 lab with Hong Kong Polytechnic University to accelerate breakthroughs and train new talents. It also recently announced that it is opening all four core pillar technologies to Hong Kong industry partners.
Under Project Ensemble, Ant International worked on two use cases for global liquidity management with Standard Chartered and HSBC, leveraging its Whale blockchain platform to enable real-time cross-border, cross-currency institutional settlements. Following the collaboration in the Sandbox, Ant International also supported the co-development of HSBC’s first global tokenized deposits solution for its corporate clients.
Through Alipay+, the global wallet gateway service under Ant International, AI payment and growth agents are rolling out not only to the 4.5 million Hong Kong active users and businesses through AlipayHK, the City’s largest digital and financial services platform, but also partner wallets in Southeast Asia and beyond.
Expanding Cross-Border Financial Services from Hong Kong for Chinese Businesses to Go Global
In October, Hong Kong launched the GoGlobal Task Force – a one-stop support platform aimed at helping Chinese mainland enterprises expand their international business using Hong Kong as a strategic base.
Under Ant International, Antom, the unified merchant payment service, provides integrated payment facilitation and growth solutions to China’s travel, digital and entertainment (D&E) and electric vehicle (EV) leaders. WorldFirst, a payment and financial services hub for SMEs, already supports 50,000 cross-border businesses in global e-commerce.
“Hong Kong has a lot of advantages as a GoGlobal centre for Chinese businesses – world-leading financial systems, outstanding professional services, and a pool of talents with global insights and knowledge,” said Jing. “We look forward to expanding our cross-border payment, account and trade financing services from here to help more Chinese companies reach overseas markets and capital.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20251102787084/en/
Contacts
Media Contact:
Shen Le, Ant Group
shenle.sl@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom